

medicare



Fabry disease – migalastat – initial grandfather authority application

When to use this form

Use this form to apply for **initial grandfather** PBS-subsidised migalastat for patients 12 years or over with Fabry disease who have received treatment with migalastat or Enzyme Replacement Therapy for the same condition funded under the Australian Government's Life Saving Drugs Program (LSDP) prior to **1 September 2024**.

Important information

Initial grandfather applications to start PBS-subsidised treatment must be in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for Fabry disease **initial grandfather** authority applications.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing treatment

This form is ONLY for **initial grandfather** treatment.

A patient may qualify for PBS-subsidised treatment under this restriction once only.

After a written authority application for **initial grandfather** treatment has been approved, applications for **continuing** treatment can be made in real time using the **Online PBS Authorities** system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Treatment specifics

 $Confirmation \ of \ eligibility \ for \ treatment \ with \ diagnostic \ reports \ including \ the \ confirmed \ mutations \ must \ be$

documented in the patient's medical records.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

PB374.2409 1 of 3





Fabry disease – migalastat – initial grandfather authority application



Patient's details		Conditions and criteria	
1	Medicare card number Ref no.	To qualify for PBS authority approval, the following conditions must be met.	
	or Department of Veterans' Affairs card number	7 Is the patient, 12 years or over, being treated by a physician with expertise in the management of Fabry disease? Yes No	I
2	Dr Mr Mrs Miss Ms Other Family name	8 Prior to 1 September 2024, the patient has previously receive treatment for this condition funded under the Australian Government's LSDP with:	ived
	First given name	migalastat or Enzyme Replacement Therapy.	
3	Date of birth (DD MM YYYY)	9 Prior to commencing treatment with this drug, did the patie have a documented migalastat amenable galactosidase alpha (GLA) gene variant?	nt
Pro	escriber's details	Yes UNION NO UNION NE UNION NO UNIONE UNION NO UNION NO UNIONE UNION NO UNI	
4 5	Prescriber number Dr Mr Mrs Miss Ms Other Family name	10 Prior to commencing treatment with this drug, did the patie have an estimated glomerular filtration rate (eGFR) of at lea 30 mL/min/1.73 m²? Yes No	
		Checklist	
	First given name	11 The relevant attachments need to be provided with this form.]
6	Business phone number (including area code)	Details of the proposed prescription(s).	
	Alternative phone number (including area code)	Privacy notice	
		12 Personal information is protected by law (including the Privacy Act 1988) and is collected by Services Australia for purposes of assessing and processing this authority applica	

Personal information is protected by law (including the
Privacy Act 1988) and is collected by Services Australia for the
purposes of assessing and processing this authority application.
Personal information may be used by Services Australia, or
given to other parties where the individual has agreed to this, or
where it is required or authorised by law (including for the
purpose of research or conducting investigations).

More information about the way in which Services Australia
manages personal information, including our privacy policy, can
be found at servicesaustralia.gov.au/privacypolicy



MCA0PB374 2409

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at

servicesaustralia.gov.au/hpos

13 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine.
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application.
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction.
- the information I have provided in this form is complete and correct.

I understand that:

• giving false or misleading information is a serious offence.		
I have read, understood and agree to the above.		
Date (DD MM YYYY) (you must date this declaration)		
Prescriber's signature (only required if returning by post)		

Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

 online (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos

or

 by post (signature required) to Services Australia Complex Drugs Programs Reply Paid 9826 HOBART TAS 7001